$CURR news alert this morning: Proceeds Will Be Us
Post# of 88930
(Total Views: 100)
Posted On: 07/28/2022 10:47:57 AM
$CURR news alert this morning: Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology
OXNARD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that it has sold a portion of its platform technology intellectual property and related assets for $20 million in total consideration. CURE used a portion of the cash proceeds to pay down certain debt obligations and the balance will be used to grow its intellectual property portfolio and its wellness and beauty brands. In addition, CURE retained its remaining proprietary platform technology that it intends to monetize through the commercialization of the technology or through the licensing or sale of the technology.
CURE will host a conference call on August 3, 2022 to provide a full corporate update to shareholders. Details of the conference call will be made available on August 1, 2022 in a follow-up press release.
OXNARD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that it has sold a portion of its platform technology intellectual property and related assets for $20 million in total consideration. CURE used a portion of the cash proceeds to pay down certain debt obligations and the balance will be used to grow its intellectual property portfolio and its wellness and beauty brands. In addition, CURE retained its remaining proprietary platform technology that it intends to monetize through the commercialization of the technology or through the licensing or sale of the technology.
CURE will host a conference call on August 3, 2022 to provide a full corporate update to shareholders. Details of the conference call will be made available on August 1, 2022 in a follow-up press release.
(0)
(0)Scroll down for more posts ▼